Navigation Links
Study shows carvedilol is effective in preventing variceal bleeding in cirrhotic patients
Date:8/19/2009

Patients with cirrhosis are at risk for developing portal hypertension that can lead to the formation, dilation, and rupture of esophageal varices. The annual incidence of esophageal varices is approximately 5% and one third of those will bleed.

In a recent study, researchers from the University of Edinburgh determined carvedilol was more effective in the prevention of variceal hemorrhaging than variceal band ligation (VBL), a common treatment used for the past 20 years. The results of the first clinical trial to test carvedilol for prevention of variceal hemorrhage are available in Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

Dhiraj Tripathi and colleagues at the Royal Infirmary of Edinburgh enlisted 152 cirrhotic patients with grade II or larger esophageal varices that had not bled in this study. Researchers treated 77 patients with carvedilol, a non-cardioselective beta-blocker (NSBB) marketed under the trade name Eucardic (Roche), while 75 patients underwent VBL every two weeks until eradication. Patients were administered carvedilol orally at a starting dose of 6.25 mg per day, increasing to a target dose of 12.5 mg per day.

Results showed 10% of patients receiving carvedilol and 23% of patients treated by VBL experienced variceal bleeding during the follow-up period. There was no difference in survival rates between the two groups. "The greater efficacy of carvedilol in the prevention of the first variceal bleed is an important finding of this study," said Dr. Tripathi. "No other randomized trial has demonstrated drug therapy to have an advantage over VBL."

While researchers concluded carvedilol had greater effectiveness in treating portal hypertension than endoscopic therapy, there were limitations to their study. "Measurements of hepatic venous-pressure gradient (HVPG) were not included as part of the study, making it difficult to determine if the benefit of carvedilol was due to a greater HVPG response or failure of the VBL, noted Dr. Jaime Bosch of the Hepatic Hemodynamic Laboratory Hospital Clinic in Barcelona, Spain in his editorial published in the September issue of Hepatology. HVPG is a standard measure used to determine portal vein pressure with variceal bleeding occurring at gradients of + 12 mm HG.

Propranolol, another NSBB drug commonly used to treat portal hypertension, was not included as part of this study. "Further studies are required to assess whether carvedilol is a better option than standard NSBB," added Dr. Bosch.


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
2. Thomson Reuters Study Finds Impact of Recession Easing on U.S. Hospitals
3. Retirees health-care benefits at risk, study warns
4. Lilly Reports on Outcome of Phase III Study of Arzoxifene
5. New study finds links between video-game playing and health risks in adults
6. Gen-Probe Begins U.S. Clinical Study of APTIMA(R) Trichomonas Vaginalis Assay on the TIGRIS(R) System
7. Study shows how to boost value of Alzheimers-fighting compounds
8. Low-income kids report first sexual intercourse at 12 years old in new national study
9. Excessive exercise can be addicting, new study says
10. New study expands the list of hazardous chemicals in smokeless tobacco
11. Summer heat increases risk of amniotic fluid level deficiency, Ben-Gurion University study reveals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Bo Chen, PhD is the ... will receive his award during the Plenary Session at ASLMS 2017, the Annual Conference ... in San Diego, California April 5-9, 2017. , During the Plenary Session on ...
(Date:2/27/2017)... ... February 27, 2017 , ... It’s no secret that ... leads to a host of health issues, including urinary incontinence. However, results published ... discovered that good overall muscle strength in older women, particularly in the abdominal ...
(Date:2/27/2017)... ... February 27, 2017 , ... Hotze Health & Wellness ... Brandl as its New Guest Director. , Brandl is a dynamic and ... career. He began his professional career at Omnium Worldwide, now known as West ...
(Date:2/27/2017)... ... 2017 , ... Robert E. Burke, MD, PhD, had a successful career as ... life experiences could have led him down a much different path. , In his ... Perseverance and Pediatrics,” Dr. Burke shares a personal account of the tribulations he encountered ...
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata Ananda of ... is happy to announce her “Spring Rejuvenation in Sedona” personally tailored retreats. For ... offer the winter-weary soul an excellent opportunity to come out of hibernation and ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017 The report "(CTMS)  Clinical Trial Management ... Based, Site Based), By Delivery Mode (Web, Cloud, On Premise), By End ... Report, Regional Outlook (U.S., Canada , Germany ... , Russia , China , ... Korea , Taiwan , Brazil ...
(Date:2/27/2017)... -- Halyard Health, Inc. (NYSE: HYH ) today ... 2017 outlook and related key planning assumptions. Executive Summary ... 2 percent increase compared to the prior year. ... million compared to net income of $15 million in the ... $24 million compared to adjusted net income of $27 million ...
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
Breaking Medicine Technology: